Breaking News Instant updates and real-time market news.

KOD

Kodiak Sciences

$12.74

0.7 (5.81%)

16:01
07/28/19
07/28
16:01
07/28/19
16:01

Kodiak Sciences announces interim data from ongoing Phase 1B study of KSI-301

Kodiak Sciences announced positive interim results from the ongoing Phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naive neovascular age-related macular degeneration, diabetic macular edema, and macular edema due to retinal vein occlusion. Across all three diseases under study, strong improvements in vision and retinal anatomy were observed over 12 weeks. The efficacy data presented at ASRS include outcomes from 35 patients in the study who had reached the week 12 visit. In the study, patients are being treated with three monthly doses of either 2.5 mg or 5 mg KSI-301 and followed for 7 months thereafter, with additional treatments according to protocol-specified retreatment criteria. A total of 200 injections with KSI-301 have been given to date across the Phase 1a and Phase 1b program with no intraocular inflammation or ocular serious adverse events reported. As of the July 24, 2019 ASRS presentation's data cut-off date, a total of 77 patients were enrolled in the Phase 1b study. Multiple-dose exposure to KSI-301 has been well tolerated. A total of 77 patients have received one injection, 60 patients have received two injections and 44 patients have received three injections. No drug-related adverse events or serious adverse events have been reported. Most of the adverse events reported have been assessed as mild and are consistent with the profile of intravitreally-injected anti-VEGF agents. Eight non-ocular serious adverse events have been reported in four patients, none being assessed as drug-related. The Phase 1b study of KSI-301 is nearing completion of enrollment of the planned cohorts. Based on the positive data observed to date, Kodiak is planning for supplemental cohorts to explore additional scientific questions relevant to KSI-301 and its use for the treatment of retinal diseases. Recruitment in a Phase 2 head-to-head trial of KSI-301 versus aflibercept in treatment-naive wet AMD patients is expected to begin in the third quarter of 2019. In this study, called DAZZLE, approximately 364 patients are planned to be enrolled worldwide. Patients will be randomized to receive either KSI-301 on a dosing regimen as infrequently as every 20 weeks or standard-care aflibercept on its every 8-week dosing regimen. All patients randomized to KSI-301 will be on an every 12-week or longer regimen after three monthly loading doses.

  • 09

    Sep

KOD Kodiak Sciences
$12.74

0.7 (5.81%)

10/29/18
LEHM
10/29/18
INITIATION
Target $20
LEHM
Overweight
Kodiak Sciences initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Kodiak Sciences with an Overweight rating and $20 price target.
10/29/18
10/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with a Buy at Jefferies. 2. Ralph Lauren (RL) initiated with a Buy at Deutsche Bank. 3. Guardant Health (GH) initiated with an Outperform at Cowen and William Blair, an Overweight at JPMorgan, and a Neutral at BofA/Merrill. 4. Kodiak Sciences (KOD) initiated with a Buy at BofA/Merrill, as well as an Overweight at Barclays and Morgan Stanley. 5. Proteostasis (PTI) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/20/19
CHDN
02/20/19
INITIATION
Target $22.5
CHDN
Buy
Kodiak Sciences initiated with a Buy at Chardan
Chardan initiated Kodiak Sciences with a Buy and $22.50 price target.
02/20/19
02/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kodiak Sciences (KOD) initiated with a Buy at Chardan. 2. Veeva (VEEV) initiated with an Equal Weight at Barclays. 3. Agios Pharmaceuticals (AGIO) assumed with a Perform at Oppenheimer. 4. OrthoPediatrics (KIDS) initiated with an Outperform at JMP Securities. 5. Homology Medicines (FIXX) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

OXY

Occidental Petroleum

$38.10

-0.34 (-0.88%)

09:55
11/13/19
11/13
09:55
11/13/19
09:55
Hot Stocks
Breaking Hot Stocks news story on Occidental Petroleum »

Occidental sees proceeds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$7.21

0.16 (2.27%)

, TSN

Tyson Foods

$89.50

0.505 (0.57%)

09:55
11/13/19
11/13
09:55
11/13/19
09:55
Options
Early notable gainers among liquid option names on November 13th »

Notable gainers among…

PCG

PG&E

$7.21

0.16 (2.27%)

TSN

Tyson Foods

$89.50

0.505 (0.57%)

XEC

Cimarex Energy

$45.15

0.15 (0.33%)

CME

CME Group

$204.28

2.74 (1.36%)

KSU

Kansas City Southern

$152.51

0.15 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 07

    Jan

09:55
11/13/19
11/13
09:55
11/13/19
09:55
Conference/Events
Senate Health, Ed, Labor & Pensions Committee to hold a hearing »

The Committee holds a…

09:55
11/13/19
11/13
09:55
11/13/19
09:55
Conference/Events
House Permanent Select Committee on Intelligence to hold a hearing »

The Committee holds a…

OVID

Ovid Therapeutics

$2.47

0.01 (0.41%)

09:54
11/13/19
11/13
09:54
11/13/19
09:54
Conference/Events
Ovid Therapeutics management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

NUE

Nucor

$55.09

-0.23 (-0.42%)

09:52
11/13/19
11/13
09:52
11/13/19
09:52
Conference/Events
Nucor management to meet with KeyBanc »

Management participates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

09:52
11/13/19
11/13
09:52
11/13/19
09:52
Conference/Events
House Judiciary Committee to hold a hearing »

The Subcommittee on…

09:50
11/13/19
11/13
09:50
11/13/19
09:50
General news
Fed Chair Powell's said policy is appropriate as long as the economy remains on track »

Fed Chair Powell's…

NSSC

Napco Security

$28.01

(0.00%)

09:49
11/13/19
11/13
09:49
11/13/19
09:49
Conference/Events
Napco Security management to meet with Oppenheimer »

Meeting to be held in St.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

MRNA

Moderna

$17.96

-0.03 (-0.17%)

09:48
11/13/19
11/13
09:48
11/13/19
09:48
Conference/Events
Moderna management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

HZN

Horizon Global

$3.72

-0.04 (-1.06%)

09:47
11/13/19
11/13
09:47
11/13/19
09:47
Hot Stocks
Horizon Global falls -6.9% »

Horizon Global is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$4.52

-0.115 (-2.48%)

09:47
11/13/19
11/13
09:47
11/13/19
09:47
Hot Stocks
SandRidge Energy falls -7.5% »

SandRidge Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

I

Intelsat

$18.47

-1.92 (-9.42%)

09:47
11/13/19
11/13
09:47
11/13/19
09:47
Hot Stocks
Intelsat falls -11.9% »

Intelsat is down -11.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

SPB

Spectrum Brands

$55.94

4.75 (9.28%)

09:47
11/13/19
11/13
09:47
11/13/19
09:47
Hot Stocks
Spectrum Brands rises 9.1% »

Spectrum Brands is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LN

Line Corp.

$40.67

(0.00%)

09:47
11/13/19
11/13
09:47
11/13/19
09:47
Hot Stocks
Line Corp. rises 13.0% »

Line Corp. is up 13.0%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENR

Energizer

$48.40

6.39 (15.21%)

09:47
11/13/19
11/13
09:47
11/13/19
09:47
Hot Stocks
Energizer rises 15.4% »

Energizer is up 15.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 21

    Nov

MDLZ

Mondelez

$52.07

-0.01 (-0.02%)

09:46
11/13/19
11/13
09:46
11/13/19
09:46
Conference/Events
Mondelez management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

09:45
11/13/19
11/13
09:45
11/13/19
09:45
Conference/Events
Senate Environment & Public Works Committee to hold a hearing »

The Committee holds a…

CTAS

Cintas

$252.52

-6.38 (-2.46%)

09:45
11/13/19
11/13
09:45
11/13/19
09:45
Hot Stocks
Cintas falls after Spruce Point sees 'fraud,' 60%-75% downside risk »

Shares of Cintas are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMT

Kennametal

$33.99

(0.00%)

09:44
11/13/19
11/13
09:44
11/13/19
09:44
Conference/Events
Kennametal management to meet with Seaport Global »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

KALA

Kala Pharmaceuticals

$3.66

(0.00%)

09:43
11/13/19
11/13
09:43
11/13/19
09:43
Conference/Events
Kala Pharmaceuticals management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

IMAX

Imax

$21.26

(0.00%)

09:42
11/13/19
11/13
09:42
11/13/19
09:42
Conference/Events
Imax management to meet with B. Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

TECK

Teck Resources

$16.55

(0.00%)

, PAAS

Pan American Silver

$17.82

(0.00%)

09:40
11/13/19
11/13
09:40
11/13/19
09:40
Options
Unusually active option classes on open November 13th »

Unusual total active…

TECK

Teck Resources

$16.55

(0.00%)

PAAS

Pan American Silver

$17.82

(0.00%)

GOOS

Canada Goose

$39.05

(0.00%)

VIPS

Vipshop

$12.03

(0.00%)

GOLD

Barrick Gold

$16.44

(0.00%)

XME

SPDR S&P Metals & Mining

$27.34

(0.00%)

LK

Luckin Coffee

$19.00

(0.00%)

WMT

Walmart

$119.13

(0.00%)

AMRN

Amarin

$20.94

(0.00%)

TSLA

Tesla

$349.89

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

  • 09

    Dec

  • 28

    Dec

  • 21

    Feb

IDSY

I.D. Systems

$0.00

(0.00%)

09:39
11/13/19
11/13
09:39
11/13/19
09:39
Conference/Events
I.D. Systems management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CTAS

Cintas

$258.90

-1.54 (-0.59%)

09:39
11/13/19
11/13
09:39
11/13/19
09:39
Hot Stocks
Breaking Hot Stocks news story on Cintas »

Cintas down 3% to $251.45…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.